VII. The role of the microenvironment in lymphoid cancers

Annals of Oncology

Volumn 22, Issue , 2011, Pages iv47-iv50

  Gascoyne, R D ^a   Steidl, C ^a  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85081559746     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr173     Document Type: Conference Paper

References (35)

1. Dave, S.S., Wright, G., Tan, B., et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351 (2004), 2159–2169.
2. Lenz, G., Wright, G., Dave, S.S., et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359 (2008), 2313–2323.
3. Anderson, J.R., Armitage, J.O., Weisenburger, D.D., Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 9 (1998), 717–720.
4. Salles, G., Seymour, J.F., Offner, F., et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377 (2011), 42–51.
5. Koster, A., van Krieken, J.H., Mackenzie, M.A., et al. Increased vascularization predicts favorable outcome in follicular lymphoma. Clin Cancer Res 11 (2005), 154–161.
6. de Jong, D., Koster, A., Hagenbeek, A., et al. Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols. Haematologica 94 (2009), 70–77.
7. Farinha, P., Al-Tourah, A., Gill, K., et al. The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. Blood 115 (2010), 289–295.
8. Farinha, P., Kyle, A.H., Minchinton, A.I., et al. Vascularization predicts overall survival and risk of transformation in follicular lymphoma. Haematologica 95 (2010), 2157–2160.
9. Farinha, P., Masoudi, H., Skinnider, B.F., et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 106 (2005), 2169–2174.
10. Canioni, D., Salles, G., Mounier, N., et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL–2000 Trial. J Clin Oncol 26 (2008), 440–446.
11. Taskinen, M., Karjalainen-Lindsberg, M.L., Nyman, H., et al. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res 13 (2007), 5784–5789.
12. Glas, A.M., Knoops, L., Delahaye, L., et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. Journal of clinical oncology 25 (2007), 390–398.
13. Yang, Z.Z., Novak, A.J., Stenson, M.J., et al. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 107 (2006), 3639–3646.
14. Yang, Z.Z., Novak, A.J., Ziesmer, S.C., et al. Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Res 66 (2006), 10145–10152.
15. Yang, Z.Z., Novak, A.J., Ziesmer, S.C., et al. Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma. Cancer Res 69 (2009), 5522–5530.
16. Hilchey, S.P., De, A., Rimsza, L.M., et al. Follicular lymphoma intratumoral CD4+CD25+GITR+ regulatory T cells potently suppress CD3/CD28-costimulated autologous and allogeneic CD8+CD25– and CD4+CD25– T cells. J Immunol 178 (2007), 4051–4061.
17. Pangault, C., Ame-Thomas, P., Ruminy, P., et al. Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent T(FH)-B cell axis. Leukemia 24 (2010), 2080–2089.
18. Irish, J.M., Myklebust, J.H., Alizadeh, A.A., et al. Inaugural Article: B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. Proc Natl Acad Sci USA 107 (2010), 12747–12754.
19. Swerdlow, S.H., Campo, E., Harris, N.L., et al. WHO classification of tumours of hematopoietic and lymphoid tissues. 2008, IARC Press, Lyon.
20. Nelson, B.H., CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol 185 (2010), 4977–4982.
21. Burger, J.A., Ghia, P., Rosenwald, A., Caligaris-Cappio, F., The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 114 (2009), 3367–3375.
22. Houot, R., Goldstein, M.J., Kohrt, H.E., et al. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood 114 (2009), 3431–3438.
23. Rosenwald, A., Wright, G., Chan, W.C., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346 (2002), 1937–1947.
24. Rimsza, L.M., Roberts, R.A., Miller, T.P., et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 103 (2004), 4251–4258.
25. Roberts, R.A., Wright, G., Rosenwald, A.R., et al. Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival. Blood 108 (2006), 311–318.
26. Rimsza, L.M., Farinha, P., Fuchs, D.A., et al. HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen. Leuk Lymphoma 48 (2007), 542–546.
27. Meyer, P.N., Fu, K., Greiner, T., et al. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab. Am J Clin Pathol 135 (2011), 54–61.
28. Green, M.R., Monti, S., Rodig, S.J., et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116 (2010), 3268–3277.
29. Chetaille, B., Bertucci, F., Finetti, P., et al. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood 113 (2009), 2765–3775.
30. Devilard, E., Bertucci, F., Trempat, P., et al. Gene expression profiling defines molecular subtypes of classical Hodgkin's disease. Oncogene 21 (2002), 3095–3102.
31. Sanchez-Aguilera, A., Montalban, C., de la Cueva, P., et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood 108 (2006), 662–668.
32. Steidl, C., Lee, T., Shah, S.P., et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 362 (2010), 875–885.
33. Steidl, C., Farinha, P., Gascoyne, R.D., Macrophages predict treatment outcome in Hodgkin's lymphoma. Haematologica 96 (2011), 186–189.
34. Steidl, C., Shah, S.P., Woolcock, B.W., et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 471 (2011), 377–381.
35. Berger, R., Rotem-Yehudar, R., Slama, G., et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 14 (2008), 3044–3051.